GENB
Generate Biomedicines, Inc.
13.49
-0.29 (-2.10%)
52w low 11.00
22.67 high
21.3% of range
Financial Analysis
| Ratio | Dec 24 | Dec 25 | Trend |
|---|---|---|---|
| Profitability | |||
| Operating Margin | -962.6% | -737.0% | |
| EBITDA Margin | -800.2% | -653.7% | |
| Net Margin | -849.4% | -637.0% | |
| FCF Margin | -592.4% | -640.1% | |
| Returns | |||
| Return on Equity | 40.0% | 33.0% | |
| Return on Assets | -33.5% | -61.5% | |
| Return on Inv Capital | 41.3% | 36.0% | |
| Liquidity | |||
| Current Ratio | 4.70x | 2.85x | |
| Quick Ratio | 4.70x | 2.85x | |
| Cash Ratio | 2.03x | 1.48x | |
| Leverage | |||
| Debt / Equity | -0.18x | -0.11x | |
| Interest Coverage | -84.54x | -195.13x | |
| Equity Multiplier | -1.19x | -0.54x | |
| Efficiency | |||
| Asset Turnover | 0.04x | 0.10x | |
| Effective Tax Rate | -0.1% | -0.1% | |
| Op CF / Net Income | 0.68x | 0.99x | |
| Investment | |||
| Capex / Revenue | 16.8% | 11.0% | |
| R&D / Revenue | 856.9% | 704.5% | |
| SG&A / Revenue | 205.7% | 132.5% | |
Revenue CAGR
+55.9%
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
+55.9%